Welcome to our dedicated page for Neogen news (Ticker: NEOG), a resource for investors and traders seeking the latest updates and insights on Neogen stock.
Neogen Corporation (NASDAQ: NEOG) provides essential solutions for food safety and animal health through advanced diagnostic technologies. This page serves as the definitive source for official company news, offering investors and industry professionals timely updates on developments impacting global food security and veterinary practices.
Access curated press releases and announcements covering financial results, product launches, strategic partnerships, and regulatory milestones. Our aggregation ensures you stay informed about NEOG's innovations in pathogen detection, molecular testing platforms, and biosafety initiatives without needing to monitor multiple sources.
All content is verified for accuracy and relevance, providing a trustworthy resource for understanding Neogen's market position and technological advancements. Key updates include progress in genomic testing, international expansion efforts, and collaborations with agricultural regulators.
Bookmark this page or check back regularly for unfiltered access to Neogen's corporate communications and critical updates that shape the future of food and animal safety industries.
Neogen (NASDAQ: NEOG) has announced a change to its second-quarter earnings release date due to U.S. equity markets being closed for the National Day of Mourning for former U.S. President Jimmy Carter. The company will now release its second-quarter earnings before market opening on Friday, January 10, 2025.
Company executives will host a webcast and conference call at 8:00 a.m. Eastern time to discuss the financial results. The call can be accessed via phone at (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international). A replay will be available after the call through Neogen's Investor Relations website.
Neogen (NASDAQ: NEOG) has announced it will release its second-quarter earnings before market opening on Thursday, January 9, 2025. The company will host a webcast and conference call at 8:00 a.m. Eastern time to discuss the financial results. Investors can access the call via phone at (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international). A live webcast will be available through Neogen's Investor Relations webpage. A replay of both the call and webcast will be accessible afterward using specific dial-in numbers and entry code 39384#.
Neogen (NASDAQ: NEOG) has launched the Petrifilm Bacillus cereus Count Plate, a new food safety testing solution. The innovative product provides a simplified method for detecting Bacillus cereus bacteria, delivering results in as few as 20 hours. The ready-to-use plate tests for the entire sensu lato groups, including B. cytotoxicus, while eliminating traditional agar method prep work.
The product enhances Neogen's established Petrifilm line, which has been trusted in microbial testing for over 40 years. This launch aims to address critical food safety needs with improved efficiency and reliability in laboratory testing protocols.
Neogen (NASDAQ: NEOG) has announced its participation in the 36th Annual Piper Sandler Healthcare Conference in New York City. The event will take place on Wednesday, December 4, 2024, featuring a presentation by John Adent, Neogen's President and CEO, at 11:00 a.m. Eastern Time. The presentation and webcast materials will be accessible through the Events & Presentations section of Neogen's Investor Relations website.
Neogen (NASDAQ: NEOG) has announced its participation in the 2024 UBS Global Healthcare Conference. The event will take place on Tuesday, November 12, in Rancho Palos Verdes, California. This participation represents an opportunity for Neogen to engage with healthcare industry stakeholders and investors at a significant industry event.
Neogen (NASDAQ: NEOG) announced its first-quarter results for fiscal year 2025, ending August 31, 2024. The company reported revenue of $217.0 million, a 5.3% decrease from the previous year. Neogen experienced a net loss of $12.6 million, or $(0.06) per diluted share, compared to a net income of $1.5 million in the prior year. Adjusted Net Income was $14.4 million, or $0.07 per diluted share, while Adjusted EBITDA reached $43.7 million.
The Food Safety segment saw a 4.2% decrease in revenue to $159.3 million, while the Animal Safety segment experienced an 8.1% decline to $57.6 million. Despite challenges, Neogen is maintaining its full-year guidance, expecting revenue between $925 million and $955 million, with Adjusted EBITDA ranging from $215 million to $235 million.
Neogen (NASDAQ: NEOG) has announced the appointment of Thierry Bernard as a new director to its Board, effective November 1, 2024. Bernard, the current CEO of QIAGEN N.V., brings extensive experience in science and technologies relevant to Neogen's markets. Jim Borel, Neogen's Board Chair, expressed confidence that Bernard's expertise will provide significant value during the company's continued growth.
Bernard has been CEO of QIAGEN since March 2020, after joining the company in 2015. His prior experience includes 15 years at bioMérieux SA, where he held various senior roles, including Corporate Vice President of Global Commercial Operations, Investor Relations, and the Greater China Region. This appointment aligns with Neogen's commitment to enhancing global food security.
Neogen (NASDAQ: NEOG) has announced the release date for its first-quarter earnings report. The company will issue the report before the market opens on Thursday, October 10, 2024. Following the release, Neogen executives will host a webcast and conference call at 8:00 a.m. Eastern time to discuss the financial results.
Investors can access the conference call by dialing (800) 836-8184 (U.S.) or +1 (646) 357-8785 (international) and requesting the Neogen First Quarter 2025 Earnings Call. A live webcast will also be available through Neogen's Investor Relations webpage. A replay of both the call and webcast will be accessible shortly after the event concludes.
Neogen (NASDAQ: NEOG) has announced its participation in the 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. The event is scheduled for Thursday, September 5, with David Naemura, Neogen's Chief Financial Officer, set to present at 3:00 PM Eastern Time.
Investors and interested parties can access the webcast and presentation materials through the Events & Presentations section of Neogen's Investor Relations website. This conference provides an opportunity for Neogen to showcase its developments and strategies in the healthcare sector to a wider audience of industry professionals and potential investors.
Neogen (NASDAQ: NEOG) has announced a sponsorship agreement with US Equestrian to enhance equine care solutions. The partnership will focus on developing educational materials about equine botulism, a deadly neuromuscular disease affecting horses. Neogen, known for producing BotVax® B, the only USDA-approved vaccine for botulism Type B in horses, will collaborate with US Equestrian to create resources on prevention techniques and treatment protocols.
The initiative aims to raise awareness about the silent killer that can be found in hay, feed, and soil. US Equestrian members will have access to these free resources in fall 2024, coinciding with vaccination season. This partnership underscores Neogen's 30-year commitment to the equestrian community and aligns with US Equestrian's goal of providing quality resources for horse care.
